Therefore, we attempted to explore the mutual regulatory relationship between MET and VEGF signal transduction in NSCLC, in order to further clarify the potential value of combined inhibition of MET and VEGF on enhancing sensitivity to EGFR TKIs in EGFR-mutant NSCLCs with aberrant MET activation. This evidence concerns the gene MET and non-small cell lung carcinoma.